The latest research study “Central Nervous System (CNS) Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global central nervous system (CNS) therapeutics market size reached US$ 121.56 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 185.62 Billion by 2027 exhibiting a growth rate (CAGR) of 7.10% during 2022-2027.
The central nervous system (CNS) refers to an essential part of the nervous system that comprises of the brain and the spinal cord. It integrates the received information and that coordinates and controls the activities of all parts of the body. CNS therapeutics primarily includes anesthetics, anticonvulsants, CNS stimulants, muscle relaxants, narcotic analgesics, sedatives, etc. It is extensively adopted in the treatment procedures of Parkinson's disease, depression, Alzheimer's disease, epilepsy, traumatic brain, spinal cord injury, CNS cancer, etc.
Download free sample brochure: https://www.imarcgroup.com/central-nervous-system-therapeutics-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Central Nervous System (CNS) Therapeutics Market Trends and Drivers:
The rising prevalence of mental illnesses and lifestyle-associated nervous system disorders, such as anxiety, depression, hypertension, etc., is among the key factors stimulating the central nervous system (CNS) therapeutics market. Apart from this, the expanding geriatric population, who are more prone to chronic neurological ailments, including Alzheimer's disease and Parkinson's disease, is also propelling the global market.
Besides this, the inflating popularity of generic neurologic drugs across developing countries, on account of their affordability, is further fueling the market growth. Additionally, the growing innovations in nervous system treatment procedures, such as the development of gene therapy, neurostimulation tools, and neural transplantation techniques, are also driving the global market. Furthermore, the introduction of novel drug-delivery systems that provide ease of administration and availability of different dosage forms is acting as another significant growth-inducing factor.
Moreover, the increasing focus among government bodies and non-government organizations on creating awareness regarding numerous nervous system disorders and the accessibility to several treatment options is further catalyzing the global market. Apart from this, the launch of favorable guidelines to support faster approvals of pipeline drugs for neurodegenerative diseases and clinical trials that encourage the entry of new products is expected to positively influence the central nervous system (CNS) therapeutics market over the forecasted period.
Report Segmentation:
The report has been segmented the market into following categories:
Breakup by Disease:
• Neurodegenerative Diseases
o Alzheimer's Disease
o Parkinson's Disease
o Multiple Sclerosis
o Huntington's Disease
o Amyotrophic Lateral Sclerosis
o Others
• Neurovascular Diseases
• CNS Trauma
• Mental Health
o Anxiety Disorders
o Epilepsy
o Mood Disorders
o Psychotic Disorders
o Others
• Infectious Diseases
• CNS Cancer
• Others
Breakup by Application:
• Hospital
• Clinic
• Homecare
• Others
By Geography:
• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
List of Major Key Players:
The major players in the market are AstraZeneca plc, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG (Roche Holding), H. Lundbeck A/S, Merck & Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
